Larimar Therapeutics, Inc.

US$2.39As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LRMRHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (22.46%)
Div yield —
ROE (139.63%)
Biotechnology
Beta (5Y) 0.70
PE TTM —
TSR TTM (38.56%)
Mkt cap US$249.5M
ROIC (87.12%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.73
14.32%
(2.38%)
Hold 3|4|6|0|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.04
12.22%
13.28%
6.71%
6.68%
Revenue$M
23.34
23.11
23.78
23.07
9.08%
8.28%
7.59%
2.54%
Peers (US$249.5M)
Cap (US$)
PE
241.3M
—
249.9M
21.32x
Capital
TTM
5Y
10Y
Leveragex
1.330
(0.143)
(0.139)
EBIT/Intx
0.597
2.129
2.550
Own earn%
(28.44)
(44.54)
(44.89)
Sh yield%
19.47
11.15
14.41
Owners
Insiders/Inst%
1.38
36.29
Short interest%
3.84
SBC / revenue%
0.57
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
30–33
$1 testx
−1.6
Incr. ROIC%
2